About Catabasis Pharmaceuticals (NASDAQ:CATB)
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-0.84
Forward P/E Ratio-1.02
Sales & Book Value
Price / Sales61.54
Price / CashN/A
Book Value$0.51 per share
Price / Book2.08
EPS (Most Recent Fiscal Year)($1.26)
Return on Equity-175.32%
Return on Assets-120.22%
Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions
What is Catabasis Pharmaceuticals' stock symbol?
Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."
How were Catabasis Pharmaceuticals' earnings last quarter?
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.06. View Catabasis Pharmaceuticals' Earnings History.
When is Catabasis Pharmaceuticals' next earnings date?
What price target have analysts set for CATB?
6 brokers have issued 12 month price objectives for Catabasis Pharmaceuticals' stock. Their forecasts range from $2.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $5.6667 in the next twelve months. View Analyst Ratings for Catabasis Pharmaceuticals.
Who are some of Catabasis Pharmaceuticals' key competitors?
Some companies that are related to Catabasis Pharmaceuticals include Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX), Cerecor (CERC), Chembio Diagnostics (CEMI), Emisphere Technologies (EMIS), Bellerophon Therapeutics (BLPH), Molecular Templates (MTEM), Acer Therapeutics (ACER), Intec Pharma (NTEC), Otonomy (OTIC), BioXcel Therapeutics (BTAI), Adamis Pharmaceuticals (ADMP), Affimed (AFMD), Leap Therapeutics (LPTX) and Forward Pharma A/S (FWP).
Who are Catabasis Pharmaceuticals' key executives?
Catabasis Pharmaceuticals' management team includes the folowing people:
- Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 50)
- Dr. Andrew J. Nichols, Chief Scientific Officer (Age 57)
- Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
- Dr. Michael Jirousek Ph.D., Co-Founder and Member of Scientific Advisory Board (Age 59)
- Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 53)
When did Catabasis Pharmaceuticals IPO?
(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.
Has Catabasis Pharmaceuticals been receiving favorable news coverage?
News stories about CATB stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a news impact score of 0.05 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Catabasis Pharmaceuticals' major shareholders?
How do I buy shares of Catabasis Pharmaceuticals?
Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catabasis Pharmaceuticals' stock price today?
One share of CATB stock can currently be purchased for approximately $1.06.
How big of a company is Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals has a market capitalization of $38.91 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.
How can I contact Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E SuiteB14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]
MarketBeat Community Rating for Catabasis Pharmaceuticals (CATB)MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.